Status:
NOT_YET_RECRUITING
Effect of Cilostazol in Promoting Hematoma Clearance After Intracerebral Hemorrhage
Lead Sponsor:
National Taiwan University Hospital
Conditions:
ICH - Intracerebral Hemorrhage
Eligibility:
All Genders
20+ years
Phase:
PHASE2
Brief Summary
Intracerebral hemorrhage (ICH) is a dangerous form of stroke with high mortality rate. Other than evacuating the hematoma with surgical procedures, there is no current effective internal medicine trea...
Detailed Description
After the subject is sent to the emergency department, he/she will receive a CT scan to evaluate the size and location of the hematoma. ICH score will be used to evaluate the severity of the subject. ...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Adult patients (at least 20 years old, no upper limit)
- ICH located in the thalamus or basal ganglia.
- ICH score less than 3 (hematoma volume no greater than 15 ml) and was admitted within 24 hours since onset.
- The patient or his/her legal representative agrees to join this trial and accept the arrangements of tests within this trial.
- Exclusion criteria:
- ICH in the cerebral lobar areas or under the cerebellar tentorium, or ICH score greater than 3.
- Surgical intervention was suggested after evaluation
- Subject has brain trauma, structural brain disease, metabolic brain disease, neuroinflammatory disease and brain tumor.
- Subject that cannot accept image examination, including but not limited to unable to cooperate, disruption of image quality due to agitation, unstable hemodynamics, has MRI-incompatible pacemakers, has aneurysmal clip or claustrophobia.
- Subject has contraindication for using contrast medium, including chronic kidney failure (CCr \< 30ml/min) or allergic to contrast medium.
- Subject is currently pregnant or is scheduled to be pregnant within the following 6 months.
- Subject is taking other antithrombotics, including antiplatelet drugs (Aspirin, Clopidogrel, Ticagrelor) and oral anticoagulative (Warfarin, Dabigatran, Rivaroxaban Apixaban, Edoxaban) when ICH happened.
- Subject has contraindication to using Cilostazol, such as heart failure of any severity, coagulative disorders, ventricular tachycardia, ventricular fibrillation, multi-focal ventricular arrhythmia, severe tachycardic arrhythmia, unstable angina, myocardial infarction in recent 6 months, or had received coronary intervention.
- Life expectancy less than 3 months.
- Subject has known allergy to drugs used in the trial and was designated not suitable to enroll in this trial by the host.
- Subject or his/her legal representative does not agree to join this trial.
Exclusion
Key Trial Info
Start Date :
August 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2027
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06504576
Start Date
August 1 2024
End Date
May 1 2027
Last Update
July 17 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.